title: Selenium or no selenium--that is the question in tumor patients: a new controversy.
abstract: The essential trace element selenium, which is a crucial cofactor in the most important endogenous antioxidative systems of the human body, is attracting more attention from both laypersons and expert groups. The interest of oncologists mainly focuses on the following clinical aspects: protection of normal tissues, sensitizing in malignant tumors, antiedematous effect, prognostic impact of selenium, and effects in primary and secondary cancer prevention. Selenium is a constituent of the small group of selenocysteine-containing selenoproteins and elicits important structural and enzymatic functions. Selenium deficiency has been linked to increased infection risk and adverse mood states. It has been shown to possess cancer-preventive and cytoprotective activities in both animal models and humans. It is well established that it has a key role in redox regulation and antioxidant function, and hence in membrane integrity, energy metabolism, and protection against DNA damage. Recent clinical trials have shown the importance of selenium in clinical oncology. In 2009, a significant benefit of sodium selenite supplementation-with no protection of tumor cells, which is often suspected by oncologists- was shown in a prospective randomized trial in gynecologic cancer patients undergoing radiation therapy. More recently, concerns arose from 2 large clinical prevention trials (NPC, SELECT) that selenium may increase the risk of developing type 2 diabetes. Despite obvious flaws in both studies and good counterarguments, controversy remains on the possible advantages and risks of selenium in cancer prevention. However, in the light of the recent clinical trials the potential benefits of selenium supplementation in tumor patients are becoming obvious, even though further research is needed.
authors.affiliation: Lippe Hospital, Lemgo, Germany.
authors.forename: Ralph
authors.initials: R
authors.lastname: Muecke
authors.forename: Lutz
authors.initials: L
authors.lastname: Schomburg
authors.forename: Jens
authors.initials: J
authors.lastname: Buentzel
authors.forename: Klaus
authors.initials: K
authors.lastname: Kisters
authors.forename: Oliver
authors.initials: O
authors.lastname: Micke
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000975:Antioxidants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000517:prevention & control*; D012643:Selenium / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014131:Trace Elements / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D016588:Anticarcinogenic Agents; D000975:Antioxidants; D014131:Trace Elements; D012643:Selenium